Khiron Life Sciences Corp.
KHRNF · OTC
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3,385 | $4,473 | $4,643 | $3,636 |
| % Growth | -24.3% | -3.7% | 27.7% | – |
| Cost of Goods Sold | $1,732 | $2,120 | $3,148 | $2,466 |
| Gross Profit | $1,653 | $2,353 | $1,495 | $1,170 |
| % Margin | 48.8% | 52.6% | 32.2% | 32.2% |
| R&D Expenses | $215 | $618 | $548 | $371 |
| G&A Expenses | $4,066 | $3,398 | $5,201 | $4,766 |
| SG&A Expenses | $4,606 | $4,450 | $5,619 | $5,525 |
| Sales & Mktg Exp. | $540 | $1,052 | $418 | $759 |
| Other Operating Expenses | $336 | $401 | $349 | $646 |
| Operating Expenses | $5,157 | $5,469 | $6,516 | $6,195 |
| Operating Income | -$3,443 | -$3,172 | -$4,823 | -$3,110 |
| % Margin | -101.7% | -70.9% | -103.9% | -85.5% |
| Other Income/Exp. Net | $53 | $910 | -$397 | -$14,929 |
| Pre-Tax Income | -$3,451 | -$2,206 | -$5,418 | -$19,953 |
| Tax Expense | $125 | -$35 | -$6 | -$452 |
| Net Income | -$3,576 | -$2,171 | -$5,412 | -$19,501 |
| % Margin | -105.6% | -48.5% | -116.6% | -536.3% |
| EPS | -0.017 | -0.012 | -0.03 | -0.11 |
| % Growth | -44% | 61.6% | 72.5% | – |
| EPS Diluted | -0.017 | -0.012 | -0.03 | -0.11 |
| Weighted Avg Shares Out | 214,528 | 186,444 | 179,395 | 179,005 |
| Weighted Avg Shares Out Dil | 214,528 | 186,444 | 179,395 | 179,005 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $93 | $33 | $155 | $0 |
| Depreciation & Amortization | $556 | $653 | $596 | $151 |
| EBITDA | -$2,887 | -$2,519 | -$4,609 | -$2,959 |
| % Margin | -85.3% | -56.3% | -99.3% | -81.4% |